Omnitrope 45 IU Cartridge

Omnitrope 45 IU Cartridge

  • Brand: Sandoz
  • Product Code: Omnitrope 45 IU Cartridge
  • Availability: In Stock
  • $240.00



Manufacturer: Sandoz
Pharmaceutical name: Somatropin
Pack: 1 cartridge (45 IU (15mg/1.5ml))
Omnitrope is a synthetic variant of human growth hormone (HGH) made by Sandoz Pharmaceuticals. HGH is a naturally produced protein in the body that promotes the growth of bones and cartilage. Omnitrope is a recombinant protein, meaning it is created under laboratory conditions and closely resembles natural HGH. This FDA-approved product is user-friendly and provides an economical treatment option for children experiencing growth hormone deficiency. Omnitrope is available in packs of 5 and comes in 1.5ml/5mg (15iu), 1.5ml/10mg (30iu), and 1.5ml/15mg (45iu) cartridges.
 
For pediatric use, Omnitrope is prescribed to children experiencing growth failure as a result of growth hormone deficiency (GHD) or Prader-Willi syndrome (confirmed through genetic testing). It is also approved for treating SGA growth failure in children born small for their gestational age who have not caught up in growth by age 2, as well as for those with idiopathic short stature (with no identifiable cause) and Turner Syndrome (females with a single X chromosome). In adults, Omnitrope is indicated for both adult-onset and childhood-onset growth hormone deficiency.
 
Omnitrope is not recommended for children who: have acute critical illnesses, respiratory failure, cancer or active malignancies, active diabetic retinopathy (either proliferative or non-proliferative), known allergies to somatropin, closed epiphyseal plates, severe obesity, or respiratory issues related to Prader-Willi Syndrome, and those who have recently undergone trauma or surgery.
 
Before prescribing Omnitrope, it is important to watch for: signs of upper airway obstruction and sleep apnea in children with Prader-Willi Syndrome; treatment should stop if any symptoms develop; for patients with existing tumors, monitoring for progression or recurrence is needed; childhood cancer survivors treated with somatropin have a heightened risk of developing a second neoplasm, particularly meningiomas in those previously treated with head radiation; glucose levels should be closely monitored in all patients, and adjustments to anti-hyperglycemic medication may be necessary for diabetic patients as impaired glucose tolerance or diabetes can emerge; intracranial hypertension might occur but may be resolved by lowering the dose or discontinuing treatment; fluid retention is common in adults, manifesting as edema, joint pain, or carpal tunnel syndrome, necessitating a dose reduction; co-existing hormone replacement therapies should be closely observed due to an increased risk of hypopituitarism; hypothyroidism may be revealed or worsen; any child developing a limp or hip/knee pain should be evaluated for slipped capital femoral epiphysis; existing scoliosis may deteriorate; and pancreatitis should be contemplated in patients experiencing persistent severe abdominal pain.
 
Formulations containing benzyl alcohol (BA) should be avoided in premature infants or neonates (for example, 5 mg/1.5 mL Omnitrope + Bacteriostatic Water diluent for the Omnitrope 5.8 mg vial). After treatment begins, the potential risks of continuing Omnitrope should be assessed if the child exhibits any of the following: scoliosis, diabetes, cancer, hormone deficiencies, trauma, complaints of hip or knee pain, limping, or breathing difficulties. Blood glucose tests and funduscopic examinations (an eye assessment for intracranial hypertension) should be conducted before starting treatment and at regular intervals thereafter. Parents of children treated for Prader-Willi syndrome who notice any breathing difficulties, increased snoring, or changes in snoring patterns should seek medical attention.
 
Potential side effects following treatment with Omnitrope may include headaches, loss of subcutaneous fatty tissue (lipoatrophy), or skin rashes at the injection sites.
 
The administration of Omnitrope using Pen 5 is straightforward: it allows for a maximum single dose of 2.7 mg, with increments of 0.05 mg. Injections are given daily or several times per week.
 
The Pen utilizes prefilled liquid cartridges, eliminating the need for mixing or reconstituting the medication, ensuring the correct dosage is administered, and preventing waste or spillage. The Pen does not require batteries or rewinding, simplifying the process and saving the user time.